Enveric Biosciences, Inc. (ENVB)
NASDAQ: ENVB · Real-Time Price · USD
6.79
+0.68 (11.13%)
At close: Dec 5, 2025, 4:00 PM EST
6.81
+0.02 (0.29%)
After-hours: Dec 5, 2025, 7:44 PM EST
Enveric Biosciences Employees
As of December 31, 2024, Enveric Biosciences had 6 total employees, including 5 full-time and 1 part-time employees. The number of employees decreased by 1 or -14.29% compared to the previous year.
Employees
6
Change (1Y)
-1
Growth (1Y)
-14.29%
Revenue / Employee
n/a
Profits / Employee
-$1,874,319
Market Cap
4.05M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6 | -1 | -14.29% |
| Dec 31, 2023 | 7 | -19 | -73.08% |
| Dec 31, 2022 | 26 | 2 | 8.33% |
| Dec 31, 2021 | 24 | 21 | 700.00% |
| Dec 31, 2020 | 3 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ENVB News
- 1 day ago - Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2026” - Business Wire
- 9 days ago - Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates - Business Wire
- 21 days ago - Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results - Business Wire
- 6 weeks ago - Enveric Biosciences Announces Reverse Stock Split - Business Wire
- 7 weeks ago - Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance - Business Wire
- 7 weeks ago - Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal - Business Wire
- 7 weeks ago - Enveric Biosciences to Explore Digital Asset Treasury Opportunities - Business Wire
- 2 months ago - Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials - Business Wire